Skip to content
All Sections
Subscribe Now
63°F
Monday, October 7th 2024
e-Edition
Home Page
Close Menu
News
News
Crime and Public Safety
Investigative Reporting
Election
Politics
Health
Environment
Business
Best Reviews
Housing
Jobs
Local News
Local News
Long Beach
Los Angeles
Los Angeles County
Sports
Sports
High School Sports
Chargers
Rams
Lakers
Clippers
Dodgers
Angels
College Sports
UCLA Sports
USC Sports
Long Beach State sports
Kings
Ducks
Olympics
Boxing/MMA
Soccer
Horse Racing
Things To Do
Things To Do
Restaurants Food and Drink
Movies
Music + Concerts
Theater
TV and Streaming
Home + Garden
Travel
Amusement Parks
Comics
Puzzles
Events
Obituaries
Obituaries
News Obituaries
Place an Obituary
Opinion
Opinion
Editorials
Opinion Columns
Commentary
Letters to the Editor
Editorial Board
Endorsements
The Grunion
The Grunion
News
Education
Sports
Things to Do
Opinion
E-Edition
Advertising
Contact Us
SCNG Premium
The T.E.A.
Subscribe
Press-Telegram Store
Log In
Logout
Close Menu
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Account Settings
Contact Us
Log Out
Spoof a user
Get the latest news delivered daily!
Sign Up
Subscribe
Log In
Search
Press Telegram
63°F
Monday, October 7th 2024
e-Edition
News
Local News
Sports
Things to Do
Obituaries
Opinion
The T.E.A.
Trending:
4 stabbings in 9 hours
DMV scraps test for some
Marathon road closures ð
Fashion takeback law
High School Football
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
November 02, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 31, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
October 27, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
October 18, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
October 16, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
October 13, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
October 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Third Quarter Financial Results
October 10, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
September 29, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
August 22, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
July 31, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
REPL
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
July 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 25, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
May 23, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
May 08, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 02, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
May 01, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
April 20, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
April 18, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 11, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
March 27, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
March 23, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
March 22, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
March 06, 2023
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close